NCT00552396 2016-03-31
An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma
Innate Pharma
Phase 1 Completed
Clinical Trials
4 trialsNCT00999830 2016-03-24
REMYKIR
Innate Pharma
Phase 2 Completed
NCT01222286 2014-05-09
KIRMONO
Innate Pharma
Phase 2 Completed
NCT01256073 2014-02-28
A Safety and Tolerability Extension Trial Assessing Repeated Dosing of Anti-KIR (1-7F9) Human Monoclonal Antibody in Patients With Acute Myeloid Leukaemia
Innate Pharma
Phase 1 Completed